Curis Q2 2025 Earnings Report

Curis EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.99
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Curis Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Curis Announcement Details

• Quarter: Q2 2025
• Date: 8/7/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, July 31, 2025
• Conference Call Time: 8:30AM ET

Curis (NASDAQ:CRIS) is a biotechnology company headquartered in Lexington, Massachusetts, that specializes in the discovery and development of targeted therapies for cancer and immune-related diseases. Since its founding in 1998, Curis has advanced a portfolio of small-molecule drug candidates designed to modulate key signaling pathways implicated in tumor growth and immune regulation. The company’s strategy combines proprietary research with strategic partnerships to accelerate clinical and preclinical programs from the laboratory through late-stage development.

Curis’ most advanced program centers on inhibitors of the hedgehog signaling pathway, a critical regulator of cell differentiation and proliferation. The company’s lead hedgehog pathway inhibitor was licensed to Sun Pharmaceutical Industries and marketed under the trade name Odomzo™ for the treatment of locally advanced basal cell carcinoma. In addition to hedgehog inhibition, Curis has built an immuno-oncology pipeline through a collaboration with Aurigene Discovery Technologies, focusing on small molecules that target immune checkpoints such as PD-L1 and VISTA. Early-stage internal programs include inhibitors of kinases involved in oncogenic signaling and innate immunity, underscoring Curis’ breadth across both oncology and immunology.

Curis has established partnerships with major pharmaceutical and biotech firms to fund development and commercialization efforts across multiple geographies. Beyond its agreements in North America, the company has secured licensing arrangements in Europe and Asia, enabling global reach for its marketed and pipeline assets. Curis’ collaborative model has generated non-dilutive capital through milestone payments and royalties while allowing the company to focus internal resources on advancing select development candidates.

The leadership team at Curis is led by a seasoned executive with extensive experience in drug development and corporate strategy. Under this guidance, the company continues to expand its research capabilities, advance clinical trials, and explore new targets through collaborations and internal discovery efforts. With a focus on innovative science and strategic partnerships, Curis aims to deliver novel therapies that address significant unmet needs in oncology and immunology.